Sharps Technology Inc. (STSS) Stock Analysis
DELISTED 2026
What happened to Sharps Technology Inc. (STSS) stock?
Sharps Technology Inc. (STSS) no longer trades on public markets. It was delisted in May 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sharps Technology Inc. (STSS) trades at $1.27. Sharps Technology Inc. focuses on developing and selling safety syringe products, primarily the Sharps Provensa ultra-low waste space syringe. Market cap: $53.8M, Sector: Healthcare.
Last analyzed: May 9, 2026Analyst Coverage for STSS: STSS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STSS against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
STSS: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sharps Technology Inc. (STSS) Healthcare & Pipeline Overview
Sharps Technology Inc. specializes in safety syringe technology, offering the Sharps Provensa syringe designed to minimize waste in vaccine and medication administration. Operating within the medical instruments and supplies sector, the company addresses the critical need for efficient and safe injection solutions in the U.S. market.
What Is the Investment Thesis for STSS?
Sharps Technology Inc. presents a focused investment opportunity within the medical device sector, centered around its Sharps Provensa ultra-low waste syringe. The company's potential lies in capitalizing on the increasing demand for efficient and safe injection solutions, particularly in vaccine administration. A key value driver is the potential for expanded market penetration within the U.S. healthcare system. However, the company's current negative profit margin of -11724.3% raises concerns about its financial sustainability. Successful scaling of production and distribution, along with effective cost management, are critical for achieving profitability. Investors should closely monitor the company's ability to secure contracts, manage operational expenses, and demonstrate revenue growth.
Based on FMP financials and quantitative analysis
STSS Key Highlights
Market capitalization of $53.8M indicates a small-cap company with potential for growth but also higher volatility.
- Gross margin of 57.1% suggests a strong ability to control production costs relative to revenue.
- Negative profit margin of -11724.3% highlights significant challenges in achieving profitability.
- Beta of 2.07 indicates higher volatility compared to the overall market.
- Focus on Sharps Provensa, an ultra-low waste space syringe, positions the company to capitalize on the growing demand for efficient medication delivery systems.
Who Are STSS's Competitors?
STSS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.8M | 61 |
| DXR Daxor Corporation | $10.00 | -2.91% | $58.4M | 57 |
| ZTEK Zentek Ltd. | $0.60 | +3.95% | $76.6M | 63 |
| NYXH Nyxoah S.A. | $1.64 | -0.61% | $164M | 69 |
| PDEX Pro-Dex, Inc. | $65.64 | -1.02% | $210M | 80 |
| UTMD Utah Medical Products, Inc. | $71.42 | -0.97% | $227M | 87 |
| INFU InfuSystem Holdings, Inc. | $12.20 | +0.08% | $246M | 85 |
| OPSSF Opsens Inc. | $2.14 | +0.65% | $247M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STSS's Key Strengths?
Innovative Sharps Provensa syringe technology.
- Focus on reducing medication waste.
- Potential for improved patient safety.
- Strong gross margin.
What Are STSS's Weaknesses?
Negative profit margin.
- Limited product portfolio.
- Concentration on the U.S. market.
- Small market capitalization.
What Could Drive STSS Stock Higher?
Potential FDA approval for new syringe applications.
- Expansion of distribution network in the United States.
- Increasing adoption of Sharps Provensa by vaccine manufacturers.
What Are the Key Risks for STSS?
Financial-distress signal — its Altman Z-Score of -0.70 sits in the distress zone (elevated bankruptcy risk).
- Competition from established medical device companies.
- Regulatory hurdles and compliance requirements.
- Negative profit margin and financial sustainability concerns.
- Product liability claims.
What Are the Growth Opportunities for STSS?
- Expansion of Sharps Provensa adoption within vaccine administration: The increasing global focus on vaccination programs presents a significant growth opportunity for Sharps Technology. By targeting vaccine manufacturers and healthcare providers, the company can drive adoption of its ultra-low waste syringe, reducing vaccine wastage and improving overall efficiency. The global vaccines market is projected to reach $90 billion by 2028, offering a substantial addressable market for Sharps Technology's innovative syringe.
- Strategic partnerships with pharmaceutical companies: Collaborating with pharmaceutical companies to integrate Sharps Provensa into their drug delivery systems can accelerate market penetration and enhance brand recognition. By partnering with companies developing injectable medications, Sharps Technology can ensure its syringe is the preferred choice for administering these drugs. This strategy can lead to long-term contracts and recurring revenue streams, solidifying the company's position in the market.
- Geographic expansion beyond the United States: While currently focused on the U.S. market, Sharps Technology can explore opportunities to expand its reach into international markets. Countries with developing healthcare infrastructure and a growing demand for safe injection practices represent attractive targets for expansion. Adapting the Sharps Provensa syringe to meet local regulatory requirements and cultural preferences will be crucial for successful international expansion.
- Development of new syringe technologies and applications: Investing in research and development to create new syringe technologies and expand the applications of Sharps Provensa can drive long-term growth. Exploring opportunities in areas such as insulin delivery, cosmetic injections, and veterinary medicine can diversify the company's product portfolio and reduce its reliance on a single market segment. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry.
- Leveraging government initiatives and funding programs: Government initiatives aimed at improving healthcare efficiency and reducing medical waste can provide significant growth opportunities for Sharps Technology. By actively participating in these programs and seeking government funding, the company can accelerate the adoption of its Sharps Provensa syringe and contribute to broader healthcare goals. Staying informed about relevant government policies and regulations is crucial for capitalizing on these opportunities.
What Are STSS's Competitive Advantages?
- Proprietary Sharps Provensa technology with ultra-low waste design.
- Focus on safety and efficiency in medication delivery.
- Established relationships with healthcare providers in the United States.
- Potential for patents and intellectual property protection.
What Does STSS Do?
Sharps Technology Inc., established in 2017 and headquartered in Melville, New York, is a medical device company dedicated to researching, designing, developing, manufacturing, distributing, and selling safety syringe products. The company's flagship product, Sharps Provensa, is an ultra-low waste space syringe engineered to optimize the administration of vaccines and injectable medications. This innovative syringe aims to reduce medication waste, improve dosage accuracy, and enhance safety for healthcare providers and patients. Sharps Technology focuses on the United States market, catering to healthcare facilities, pharmacies, and government agencies seeking advanced injection solutions. The company's commitment to innovation and safety positions it as a key player in the evolving medical device landscape, addressing the growing demand for efficient and safe drug delivery systems.
What Products and Services Does STSS Offer?
- Researches and designs safety syringe products.
- Develops innovative syringe technologies to minimize waste.
- Manufactures safety syringes for vaccine and medication administration.
- Distributes syringes to healthcare facilities and pharmacies.
- Sells safety syringe products in the United States.
- Offers the Sharps Provensa ultra-low waste space syringe.
How Does STSS Make Money?
- Direct sales to healthcare providers and pharmacies.
- Distribution agreements with medical supply companies.
- Partnerships with pharmaceutical companies for drug delivery systems.
- Government contracts for vaccine administration programs.
What Industry Does STSS Operate In?
Sharps Technology Inc. operates in the medical instruments and supplies industry, a sector characterized by continuous innovation and stringent regulatory oversight. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Competition is intense, with established players and emerging companies vying for market share. Sharps Technology's focus on safety syringe technology aligns with the industry's emphasis on patient safety and efficient healthcare delivery. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strong relationships with healthcare providers.
Who Are STSS's Key Customers?
- Hospitals and clinics.
- Pharmacies and retail drug stores.
- Vaccine manufacturers.
- Government healthcare agencies.
Financial Health
Sharps Technology Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.70 places it in the distress zone, a signal of elevated financial risk.
How Sharps Technology Inc. Is Valued
Sharps Technology Inc. carries a market capitalization of $53.8M, placing it in the micro-cap category.
Forward Outlook
Wall Street analysts project Sharps Technology Inc. revenue of about $72.4M for fiscal 2026, with EPS near $0.00.
STSS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Community sentiment has turned positive, with discussions highlighting the company's innovative product pipeline and potential market impact.
- Analysts are noting increased interest in the healthcare sector, which could benefit Sharps Technology given its focus on medical solutions.
- Recent partnerships and collaborations have been announced, enhancing the company's visibility and credibility in the market.
Bear Case
- Concerns have been raised about the company's ability to scale production effectively, which could hinder growth in demand.
- Social sentiment includes skepticism regarding the competitive landscape, with some investors worried about market saturation.
- Recent regulatory challenges in the healthcare sector may pose risks to Sharps Technology's operations and timelines.
- There are mixed reviews about the company's financial health, with some community members expressing doubts about long-term viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
STSS Latest News
Leadership: Paul Kruger Danner
CEO
Paul Kruger Danner serves as the CEO of Sharps Technology Inc., leading the company's strategic direction and overseeing its operations. His background includes experience in managing teams and driving growth within the medical device industry. Danner is responsible for guiding the company's research, development, manufacturing, and sales efforts. His leadership is focused on expanding the adoption of Sharps Provensa and establishing Sharps Technology as a key player in the safety syringe market.
Track Record: Under Paul Kruger Danner's leadership, Sharps Technology has focused on commercializing the Sharps Provensa syringe and building relationships with healthcare providers. Key milestones include securing initial contracts and expanding the company's manufacturing capabilities. Danner's strategic decisions are centered on driving revenue growth and achieving profitability through increased market penetration and operational efficiency.
Sharps Technology Inc. Healthcare Stock: Key Questions Answered
What happened to Sharps Technology Inc. (STSS) stock?
Sharps Technology Inc. (STSS) no longer trades on public markets. It was delisted in May 2026. The figures below are historical and are not a current quote.
Can I still buy STSS shares?
No. STSS stopped trading on public markets in May 2026, so the shares are not available through a broker. Anything you see quoted for STSS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before STSS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Sharps Technology Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Sharps Technology, Inc. do?
Sharps Technology Inc. is a medical device company that specializes in the development, manufacturing, and sale of safety syringe products. Its primary product, the Sharps Provensa, is an ultra-low waste space syringe designed to minimize medication waste during vaccine and injectable medication administration.
What do analysts say about STSS stock?
Analyst coverage of Sharps Technology Inc. (STSS) is limited, reflecting its small market capitalization and emerging growth stage. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's current negative profitability. Growth considerations center on the company's ability to scale production, secure contracts, and expand market share for its Sharps Provensa syringe.
What are the main risks for STSS?
Sharps Technology Inc. faces several risks inherent to the medical device industry and its specific business model. Competition from larger, more established medical device companies poses a significant threat. Regulatory hurdles and compliance requirements can delay product approvals and increase operational costs. The company's negative profit margin raises concerns about its financial sustainability and ability to fund future growth.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is based on the most recent filings and may not be indicative of future performance.